 | Up a level |
Jazebi, M. and Baghaipour, M.R. and Bahoush, G.R. and Ala, F. and Dorgalaleh, A. and Moazezi Nekoei Asl, S.S. and Bahraini, M. and Baghaipour, N. and Tabibian, S. (2021) Inhibitor development in patients with type 3 Von Willebrand disease, a comprehensive study on 99 Iranian patients. Haemophilia.
Rassoulzadegan, M. and Ala, F. and Jazebi, M. and Enayat, M.S. and Tabibian, S. and Shams, M. and Bahraini, M. and Dorgalaleh, A. (2020) Molecular and clinical profile of type 2 von Willebrand disease in Iran: a thirteen-year experience. International Journal of Hematology, 111 (4). pp. 535-543.
Kazemi, A. and Abolghasemi, H. and Kazemzadeh, S. and Vahidi, R. and Faranoush, M. and Farsinejad, A. and Ala, F. (2017) Molecular characterization of Glanzmann's thrombasthenia in Iran: Identification of three novel mutations. Blood Coagulation and Fibrinolysis, 28 (8). pp. 681-686.
Rasighaemi, P. and Kazemi, A. and Ala, F. and Jazebi, M. and Razmkhah, F. (2010) Association of FXII 5�UTR 46C>T polymorphism with FXII activity and risk of thrombotic disease. Turkish Journal of Hematology, 27 (1). pp. 15-19.
